Quarterly ResultAug 5, 2026, 04:17 PM
OraSure Q2 Revenue $30.6M, GAAP EPS $0.09; FDA Clearances
AI Summary
OraSure Technologies announced its second quarter 2026 financial results, reporting $30.6 million in revenue, a 2% decrease year-over-year but a 9.7% sequential increase. The company achieved a GAAP net income of $6.2 million, or $0.09 diluted EPS, a significant improvement from a net loss in the prior year, largely due to a $22.6 million reduction in contingent consideration liability. OraSure also received FDA clearance for its Colli-Pee™•Dx urine collection device and Emergency Use Authorization for its OraQuick™ Ebola 2.0 Rapid Antigen Test, while repurchasing $2 million in common stock.
Key Highlights
- Q2 2026 total net revenues were $30.6 million, a 2% decrease year-over-year but up 9.7% sequentially.
- GAAP gross margin improved to 43.5% in Q2 2026 from 42.1% in Q2 2025.
- GAAP net income was $6.2 million ($0.09 diluted EPS) in Q2 2026, compared to a $19.7 million net loss ($0.26 diluted EPS) in Q2 2025.
- The company recorded a $22.6 million reduction in contingent consideration liability in Q2 2026.
- Received FDA clearance for Colli-Pee™•Dx at-home urine collection device in June 2026.
- Received FDA Emergency Use Authorization for OraQuick™ Ebola 2.0 Rapid Antigen Test in July 2026.
- Repurchased $2 million of common stock in Q2 2026, totaling $22 million out of a $40 million authorization.
- Provided Q3 2026 revenue guidance of $29.5 million to $32.5 million.
Price Impact
More from OSUR